6.3.1. treatment evaluation. response treatment assessed initial induction cycle repeat imagining and/or re-evaluation tumour markers. marker decline and/or radiologically regressing stable tumour features, planned chemotherapy completed . markers decline, metastases progress imaging, induction therapy must completed . markers normalised masses features post-pubertal teratoma progress early surgical resection considered. slow marker-decline initial one two cycles chemotherapy warrants consideration dose intensification (see https://www.gustaveroussy.fr/calculation-tumor/nsgct.html). following completion treatment, cases low-level β-hcg plateau observed determine whether complete normalisation subsequently occurs. patients low plateau serum afp level chemotherapy, removal residual masses undertaken, subsequent afp monitoring. preoperative afp levels > 30 μg/l viable cancer found histological examination resected specimen described predictors relapse first line chemotherapy . salvage chemotherapy thus indicated documented marker progression .